• Antinori A, Zaccarelli M, Cingolani A. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure[J]. AIDS Res Hum Retrov, 2002, 18(): 835-838. doi: 10.1089/08892220260190308

  • Calvez V, Costagliola D, Descamps D. Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial[J]. Antivir Ther, 2002, 7(): 211-218.

  • De Clercq E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV[J]. Int J Antimicrob Ag, 2009, 33(): 307-320. doi: 10.1016/j.ijantimicag.2008.10.010

  • Gingeras T, Mamtora G, Shen N. Genetic analysis of HIV-1 plasma using high density oligonucleotide arrays and dideoxynucleotide sequencing[J]. Antivral Therapy, 1996, 1(Suppl.1): 42-.

  • Hertogs K, de Bethune M P, Miller V. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs[J]. Antimicrob Agents Ch, 1998, 42(): 269-276. doi: 10.1093/jac/42.2.269

  • Japour A J, Mayers D L, Johnson V A, et al. 1993. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group. Antimicrob Agents Ch, 37: 1095-1101.

  • Johnson V A, Brun-Vezinet F, Clotet B. Update of the drug resistance mutations in HIV-1: Spring 2008[J]. Top HIV Med, 2008, 16(): 62-68.

  • Kantor R, Machekano R, Gonzales M J. Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database: an expanded data model integrating natural language text and sequence analysis programs[J]. Nucleic Acids Research, 2001, 29(): 296-299. doi: 10.1093/nar/29.1.296

  • Lecossier D, Shulman N S, Morand-Joubert L. Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine[J]. J Acq Immune Defic Syndr, 2005, 38(): 37-42. doi: 10.1097/00126334-200501010-00007

  • Liu P, Xiang K, Tang H. Molecular epidemiology of human immunodeficiency virus type 1 and hepatitis C virus in former blood donors in central China[J]. AIDS Res Hum Retrov, 2008, 24(): 1-6.

  • Marcelin A G, Flandre P, Pavie J. Clinically relevant genotype interpretation of resistance to didanosine[J]. Antimicrob Agents Ch, 2005, 49(): 1739-1744. doi: 10.1128/AAC.49.5.1739-1744.2005

  • Rhee S Y, Gonzales M J, Kantor R. Human immunodeficiency virus reverse transcriptase and protease sequence database[J]. Nucleic Acids Research, 2003, 31(): 298-303. doi: 10.1093/nar/gkg100

  • Shafer R W, Winters M A, Palmer S. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients[J]. Ann Intern Med, 1998, 128(): 906-911. doi: 10.7326/0003-4819-128-11-199806010-00008

  • Wensing A M, van de Vijver D A, Angarano G. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management[J]. J Infect Dis, 2005, 192(): 958-966. doi: 10.1086/jid.2005.192.issue-6

  • Yerly S, Kaiser L, Race E. Transmission of antiretroviral-drug-resistant HIV-1 variants[J]. Lancet, 1999, 354(): 729-733. doi: 10.1016/S0140-6736(98)12262-6